Innate Pharma Files 6-K with Press Release
Ticker: IPHYF · Form: 6-K · Filed: Nov 17, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Nov 17, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release, foreign-private-issuer
Related Tickers: IPHA
TL;DR
Innate Pharma (IPHA) dropped a 6-K filing on 11/17/25 with a press release - check it out.
AI Summary
Innate Pharma S.A. filed a Form 6-K on November 17, 2025, reporting information as a foreign private issuer. The filing includes a press release dated November 17, 2025, as Exhibit 99.1. Innate Pharma S.A. is a biotechnology company based in Marseille, France, and files its annual reports under Form 20-F.
Why It Matters
This filing provides an update from Innate Pharma S.A., a publicly traded company, which could contain material information for investors regarding its operations or strategic developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that typically contains press releases or other information required for foreign private issuers, without immediate indication of significant financial or operational changes.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- November 17, 2025 (date) — Filing Date and Press Release Date
- 117 Avenue de Luminy—BP 30191 13009 Marseille, France (address) — Principal Executive Office
- Form 20-F (document) — Annual Report Filing Requirement
- 6-K (document) — Filing Type
FAQ
What is the primary purpose of this Form 6-K filing by Innate Pharma S.A.?
The primary purpose of this Form 6-K filing is to report information as a foreign private issuer, including a press release dated November 17, 2025, as Exhibit 99.1.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on Friday, November 17, 2025.
Where is Innate Pharma S.A. located?
Innate Pharma S.A.'s principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Under which form does Innate Pharma S.A. typically file its annual reports?
Innate Pharma S.A. files its annual reports under cover of Form 20-F.
What is the Commission File Number for Innate Pharma S.A.'s SEC filings?
The Commission File Number for Innate Pharma S.A. is 001-39084.
Filing Stats: 160 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-11-17 06:02:00
Filing Documents
- a6k-iphx250825.htm (6-K) — 8KB
- exhibit991-250825.htm (EX-99.1) — 16KB
- 0001628280-25-052474.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date November 17, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chief Executive Officer